Topics included:
- Overview of the Decision: What the Court Actually Said
- What Is Permitted Now
- What Must Be Disclosed
- What Has Changed: Types of Communications That May Be Paid with Corporate Funds:
- Expenditures by For-Profit Corporations
- Contributions to Advocacy Organizations
- Unenforceability of FEC Regulations prohibiting Corporate Communications With Employees & Vendors
- Types of Communications Now Permitted
- Expenditures by Nonprofit Corporations & Labor Unions
- Candidate -related expenditures – express advocacy / electioneering communications
- Unenforceability of FEC Regulations Prohibiting Voter Guides & Voting Records
- Membership communications — Protected & Enlarged
- Expenditures by For-Profit Corporations
- What Has NOT Changed:
- Disclaimer Requirements
- Donor Disclosure Requirements
- Contribution And Other Limits Unchanged
- Other Cases changing the Paradigm: SpeechNOW & Emily’s List
- Impact on State Laws Prohibiting Corporate Expenditures:
- Unenforceability of State Laws Prohibiting Corporate Expenditures Related to Candidates / Electioneering Prohibitions
- Review of tax treatment of the advocacy communications addressed in Citizens United and related political and lobbying communications and activities.
- For-profit companies
- Nonprofit advocacy organizations (501(c)(4))
- Nonprofit educational and charitable organizations ((501(c)(3))
- PAC’s, campaign committees, and other 527 organizations
- Impact of Citizens United on tax rules
- Direct impact (limited)
- Indirect impact (could be substantial)
- IRS tax enforcement in light of Citizens United
For more information, please contact Elie Harris at eharris@foley.com.
People
Related Insights
13 March 2025
Delaware’s Fight to Remain Preeminent Home for Corporations
Delaware is feeling the pressure of backlash from resident corporations over recent decisions by the Delaware Court of Chancery in stockholder litigation, as well as from significant competition from other states, like Texas and Nevada, which are making material changes to their respective corporate laws to attract corporations looking for a friendlier new home state.
12 March 2025
Health Care Law Today
Compounded GLP-1 Drugs: Texas Judge Denies PI Motion and Request for Stay of FDA’s Declaration that Tirzepatide Shortage is Resolved; Plaintiff OFA Appeals
On March 5, 2025, one U.S. District Court ruled unequivocally in the Food & Drug Administration’s (FDA) favor in the case, Outsourcing Facilities Ass’n, et. al. v. U.S. Food and Drug Admin., et. al., 4:24-cv-0953-P, slip op., 2025 WL 746028, at *15 (N.D. Tex. Mar. 5, 2025), denying plaintiffs’ motion for (1) a preliminary injunction (PI) prohibiting the FDA from taking action against Outsourcing Facilities Association (OFA) members and FarmaKeio based on their compounding of the drug ingredient tirzepatide pending final judgment in the case and (2) a stay pending conclusion of the review proceedings in response to the FDA’s declaration that the shortage of the diabetes and weight-loss tirzepatide products has been resolved.
12 March 2025
Health Care Law Today
GLP-1 Receptor Agonists and Patent Strategy: Securing Patent Protection for New Use of Old Drugs
GLP-1 receptor agonists were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management (e.g., Wegovy®) and are now being explored for treating a wide range of health conditions.